Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors by Yun-Ju Chen et al.
Chen et al. Breast Cancer Research 2013, 15:R108
http://breast-cancer-research.com/content/15/6/R108RESEARCH ARTICLE Open AccessLapatinib–induced NF-kappaB activation
sensitizes triple-negative breast cancer cells to
proteasome inhibitors
Yun-Ju Chen1,2†, Ming-Hsin Yeh3†, Meng-Chieh Yu4,7†, Ya-Ling Wei4, Wen-Shu Chen4,12, Jhen-Yu Chen7,8,
Chih-Yu Shih7, Chih-Yen Tu5,6,13, Chia-Hung Chen5,9,10, Te-Chun Hsia6,9, Pei-Hsuan Chien1, Shu-Hui Liu11,14,
Yung-Luen Yu4,7,8,15 and Wei-Chien Huang4,7,8,15*Abstract
Introduction: Triple-negative breast cancer (TNBC), a subtype of breast cancer with negative expressions of
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), is frequently
diagnosed in younger women and has poor prognosis for disease-free and overall survival. Due to the lack of
known oncogenic drivers for TNBC proliferation, clinical benefit from currently available targeted therapies is limited,
and new therapeutic strategies are urgently needed.
Methods: Triple-negative breast cancer cell lines were treated with proteasome inhibitors in combination with
lapatinib (a dual epidermal growth factor receptor (EGFR)/HER2 tyrosine kinase inhibitor). Their in vitro and in vivo
viability was examined by MTT assay, clonogenic analysis, and orthotopic xenograft mice model. Luciferase reporter
gene, immunoblot, and RT-qPCR, immunoprecipitation assays were used to investigate the molecular mechanisms
of action.
Results: Our data showed that nuclear factor (NF)-κB activation was elicited by lapatinib, independent of EGFR/
HER2 inhibition, in TNBCs. Lapatinib-induced constitutive activation of NF-κB involved Src family kinase (SFK)-
dependent p65 and IκBα phosphorylations, and rendered these cells more vulnerable to NF-κB inhibition by p65
small hairpin RNA. Lapatinib but not other EGFR inhibitors synergized the anti-tumor activity of proteasome
inhibitors both in vitro and in vivo. Our results suggest that treatment of TNBCs with lapatinib may enhance their
oncogene addiction to NF-κB, and thus augment the anti-tumor activity of proteasome inhibitors.
Conclusions: These findings suggest that combination therapy of a proteasome inhibitor with lapatinib may
benefit TNBC patients.Introduction
Triple-negative breast cancer (TNBC), defined by the
lack of expression of estrogen, progesterone, and epider-
mal growth factor receptor/human epidermal growth
factor receptor 2 (ERBB2/HER2) receptors [1], repre-
sents 15% to 20% of all breast cancer cases [2] and
occurs in young premenopausal women with a higher* Correspondence: whuang@mail.cmu.edu.tw
†Equal contributors
4Center for Molecular Medicine, China Medical University and Hospital,
Taichung 404, Taiwan
7Graduate Institute of Cancer Biology, China Medical University, Taichung
404, Taiwan
Full list of author information is available at the end of the article
© 2013 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfrequency [3]. TNBC is commonly associated with basal-
like phenotype and characterized by high histological
grade, preference for brain or lung metastasis and
aggressive behavior with shorter time to recurrence and
death [1,3]. Patients with this subtype usually have a
worse clinical outcome [2]. In addition to an intricate re-
lationship with basal-like breast carcinomas, TNBC is gain-
ing attention due to its lack of effective tailored therapies.
Chemotherapy is the systemic therapy currently available
for TNBC, but no standard regimen is recommended.
Some TNBC tumors are sensitive to paclitaxel-containing
and doxorubicin-containing chemotherapies [4]. However,
TNBC patients became rapidly chemoresistant andtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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New therapeutic strategies are urgently needed.
NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) is a family of transcription factors
involved in the regulation of immune responses and
inflammation, and plays a major role in tumorigenesis of
many cancer types [7,8]. It is restricted to the cytoplasm
by binding with inhibitory IκB proteins. In response to
stimulations, IκB kinase (IKK) complex is activated to
phosphorylate IκB proteins. The phosphorylated IκB
proteins are then ubiquitinated and degraded by 26S
proteasome [9], leading to NF-κB nuclear translocation.
NF-κB controls the expressions of several pro-tumorigenic
genes which are associated with angiogenesis, apop-
tosis, invasion, migration, and cell survival [10,11]. Ab-
errant activation of NF-κB also enhances resistance to
chemotherapy in cancer cells [12]. Inactivation of NF-
κB through blocking IκB degradation by bortezomib, a
proteasome inhibitor, has shown clinical benefits for
the treatment of hematological malignancies [13]. Al-
though NF-κB activation and overexpression of its tar-
get genes have been observed in TNBC tumors [14,15],
bortezomib showed limited clinical benefits in phase II
trials [16]. These disappointing results suggest that the sur-
vival of TNBC may only be partially addicted to NF-κB.
Therefore, new strategies making TNBC more addicted to
NF-κB activity may be able to improve the therapeutic
efficacy of proteasomal inhibitors.
Lapatinib (GW572016, Tykerb), a dual EGFR and
HER2 tyrosine kinase inhibitor (TKI), has been approved
for trastuzumab-resistant HER2-positive advanced breast
cancer patients, [17]. However, acquired resistance still
occurred within six to twelve months after initial treat-
ment [18]. The elevation of NF-κB activity was found
in lapatinib-treated HER2-positive breast cancer cells
[19,20], and targeting RelA (p65) protein expression
enhanced the lapatinib-induced apoptosis [20]. Lapatinib
has recently been found to up-regulate the gene expres-
sion of proapoptotic TRAIL death receptors DR4 and
DR5 [21]. Our recent study also showed that lapatinib
can induce the NF-κB-targeted gene COX-2 in a HER2/
EGFR-independent manner [22]. These observations
raise the possibility that lapatinib may increase NF-κB
activity independently of targeting EGFR and HER2.
In this study, we demonstrated that lapatinib, but not
specific EGFR inhibitors gefitinib and erlotinib, can
induce the phosphorylation and nuclear translocation of
p65 and the subsequent expression of NF-κB target
genes in both HER2-positive and TNBC cells. We fur-
ther revealed the involvement of Src family kinase
(SFK)-dependent p65 and IκBα phosphorylations in this
event. Although lapatinib or bortezomib alone did
not elicit the expected clinical benefits for TNBC,
co-treatment can enhance the anti-tumor activity ofbortezomib by increasing the oncogenic addiction of
these cancer cells to NF-κB. These findings not only de-
cipher the molecular mechanisms of lapatinib-induced
NF-κB activation, but also suggest remarkable thera-
peutic benefits with combination of bortezomib and
lapatinib in TNBC patients.
Methods
Cell lines and reagents
All cancer cell lines were purchased from the American
Type Culture Collection (ATCC – Manassas, VA, USA)
and maintained in a humidified 5% CO2 incubator at
37°C. SkBr3, BT474, MDA-MB-231, MDA-MB-468 and
HBL100 were cultured in (Dulbecco’s) modified Eagle’s
medium ((D)MEM)/F12. HS-578 T was maintained in
Roswell Park Memorial Institute medium (RPMI). All
the media were supplemented with 10% FBS, 100 unit/
ml penicillin and 100 mg/ml streptomycin. To establish
lapatinib-, erlotinib-, and gefitinib-selected cells, cancer
cells were treated with increasing concentrations of lapa-
tinib, erlotinib, or gefitinib up to 1 μM. p65 shRNA
clones were purchased from the National RNAi Core
Facility at Academia Sinica (Taipei, Taiwan).
Protein extraction and immunoblot
For total cell lysates, cells were washed with ice-cold
PBS one time and lysed in RIPA buffer (20 mM Tris–
HCl, pH7.4, 150 mM NaCl, 1% NP-40, 1% sodium deox-
ycholate, 1 mM ethylenediaminetetraacetic acid (EDTA)
and 1 mM ethylene glycol tetraacetic acid (EGTA)). For
subcellular fractionation, the methods were done as pre-
viously described. Protease inhibitors and phosphatase
inhibitors cocktails were added in the RIPA buffer. Pro-
teins were separated by SDS-PAGE, transferred to a
polyvinylidene fluoride (PVDF) membrane and blotted
with indicated antibodies.
Immunofluorescence staining
Cells were grown on gelatin cover slips and fixed at day
2 with 4% paraformaldehyde in PBS for 15 minutes. For
immunofluorescence staining, cells were next treated
with 0.5% Triton X-100 in PBS for 15 minutes and
blocked with 10% BSA in PBS for 1 hour followed by in-
cubation with anti-p65 antibody at 4°C overnight. After
incubation with horseradish peroxidase (HRP)-labeled
secondary antibody, cells were further stained with the
nucleic acid stain, diamidino-2-phenylindole (DAPI)
(Invitrogen, Carlsbad, CA, USA), and mounted with
ProLong Gold antifade mounting reagent (Invitrogen).
Microarray analysis and ingenuity pathway analysis
Total RNA was extracted by Trizol® Reagent (Invitrogen)
according to the instruction manual. RNA was quantified
at OD260 nm by using a ND-1000 spectrophotometer
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qualitated by using a Bioanalyzer 2100 (Agilent Technology,
Santa Clara, California USA) with RNA 6000 nano labchip
kit (Agilent Technologies). Total RNA (0.5 mg) was ampli-
fied by a Quick-Amp Labeling kit (Agilent Technologies)
and labeled with Cy3 or Cy5 (CyDye, PerkinElmer, Waltham,
Massachusetts USA) during the in vitro transcription
process. CyDye-labled cRNA (0.825 mg) was fragmented
to an average size of about 50 to 100 nucleotides by
incubation with fragmentation buffer at 60°C for 30 mi-
nutes. Correspondingly fragmented labeled cRNA was
then pooled and hybridized to Agilent Human Whole
Genome Oligo 4 × 44 K Microarray (Agilent Technologies)
at 60°C for 17 hours. After washing and drying by nitrogen
gun blowing, microarrays were scanned with an Agilent
microarray scanner (Agilent Technologies) at 535 nm
for Cy3 and 625 nm for Cy5. Scanned images were
analyzed by Feature extraction 9.5.3 software (Agilent
Technologies), an image analysis and normalization soft-
ware was used to quantify signal and background intensity
for each feature, and the data substantially normalized
using the rank-consistency-filtering LOWESS method.
The data have been deposited in NCBI’s Gene Expression
Omnibus and are accessible through GEO Series acces-
sion number GSE51889 [23].
NF-κB-targeted gene expressions were overlaid onto a
global molecular network developed from information
contained in the Ingenuity Pathways Knowledge Base
(IPA Ingenuity Systems [24]). The network of these NF-
κB-targeted genes was then algorithmically generated
based on their connectivity and the molecular relationships
between these genes/gene products were presented graph-
ically. The NF-κB-targeted genes or gene products are
represented as nodes, and the biological relationship be-
tween two nodes is represented as an edge (line). All edges
are supported by at least one reference from the literature,
from a textbook, or from canonical information stored in
the Ingenuity Pathways Knowledge Base. The intensity of
the node color indicates the degree of positive (red) or
negative (green) correlation. Nodes are displayed using
various shapes that represent the functional class of the
gene product. Edges are displayed with various labels that
describe the nature of the relationship between the nodes.
RNA extraction and quantitative reverse transcription PCR
Total RNA was extracted by Trizol™ reagent (Roche,
Basel, Switzerland) and converted into cDNA with M-
MLV reverse transcriptase (Invitrogen). Synthesized cDNA
was used as the template for SYBR qPCR, and changes
in gene expression level were normalized to GAPDH in
respective cDNA samples. Primers used were as de-
scribed below: 5′-CGGACTGCCCTTCACCTCGC-3′
(IκBα, forward), 5′-GTATCCGGGTGCTTGGGCGG-
3′ (IκBα, reverse), 5′-CCCCCGACTGGACGAGAGGG-3′ (ICAM1, forward), 5′-TGAGTGCTCCTGGCCCGAC
A-3′ (ICAM1, reverse), 5′-CTTCAGGCAGGCCGCGT
CAG-3′ (IL-1β, forward), 5′-TGCTGTGAGTCCCGGA
GCGT-3′ (IL-1β, reverse), 5′-TGGCACCTGACCGGAG
CATGTA-3′ (TRAF1, forward), 5′-CAACAGGTGGCCT
CTGGGCTGT −3′ (TRAF1, reverse), and 5′GCTTAAA
CAGGAGCATCCTGA-3′ (COX-2, forward), and 5′-GG
GTAATTCCATGTTCCAGC-3′ (COX-2, reverse).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell viability assay
In vitro cell viability was measured using an MTT colori-
metric assay. Cells were trypsinized to seed at a density
of 5 × 103 to 1 × 104 cells/well in 96-well plates. After
various treatments and culturing periods, the culture
medium was removed and 100 μL of serum-free
medium with 5 mg/mL MTT solution (Sigma, St. Louis,
MO, USA), 25 μL/well, was added and the cells incu-
bated for three hours. Finally, 100 μL of dimethyl sulfox-
ide (DMSO) was added to lyse the cells and the O.D.550
wavelength was detected by ELISA reader.
Clonogenic assay
For clonogenic assay, cells were plated at 5 × 103 to 1 ×
104 cells/well in 6-well plates and pretreated with 1 μM
lapatinib or gefitinib for three days followed by addition
of MG132 or bortezomib. Colonies were fixed and
stained with 30% ethanol containing 1% crystal violet.
Reporter gene assay
Cells were seeded at 2 × 105 cells/well in 12-well plates
and transfected with the indicated plasmids in each ex-
periment, including IL-1 β promoter-luciferase plasmids
containing NF-κB binding sites. Twenty-four hours after
transfection, the luciferase activities in cell lysates were
determined by the Luciferase Assay System (Promega,
Madison, WI, USA) and normalized to β-galactosiadase
activities.
Tumor xenograft mouse model
All animal experiments were performed in accordance
with a protocol approved by the Institutional Animal
Care and Use Committee of China Medical University
and Hospital (No. 100-61-N). Female severe combined
immunodeficient (SCID) mice at 4 to 6 weeks of age
were used in the orthotopic tumor-xenograft model.
MDA-MB-231 cells (6 × 106 cells/mouse; re-suspended
in a 1:1 mixture of PBS and growth factor–reduced
Matrigel (BD Biosciences, San Jose, CA, USA) in a total
volume of 50 μL) were injected into the mammary fat
pads of SCID mice, and the tumor size was measured
regularly. Once the tumor size reached 100 mm3, mice
were treated orally with saline, lapatinib (20 mg/kg), bor-
tezomib (0.02 mg/kg), or a combination of lapatinib
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month later, all mice were sacrificed, and tumors were
resected and their size was measured. The tumor growth
rates were analyzed by measuring the tumor length (L)
and width (W) with calipers and by calculating the
volume with the formula LW2/2.
Immunohistochemical Staining
Five-micron thick paraffin-embedded tissue sections
were deparaffinized and rehydrated. The tissue sections
were incubated for two hours with mouse monoclonal
anti-human p65 and anti-Bax antibodies (100 dilution,
Santa Cruz, Dallas, Texas USA). After washing to re-
move unbound primary antibody, sections were treated
with a dextran polymer backbone conjugated to second-
ary antibodies and labeled with HRP according to the
manufacturer’s instructions (DAKO Envision system for
mouse and rabbit primary antibodies, DAKO Corpor-
ation, Carpinteria, CA, USA) for 30 minutes. Tissue sec-
tions were incubated in the chromogenic peroxidase
substrate, diaminobenzidine, for five minutes. The specifi-
city of labeling by this procedure was verified by negative
control reactions using buffer to replace the primary anti-
body and isotype-specific immunoglobulin G (IgG).
Statistical analysis
All results are presented as the mean ± SD. A two-tailed
Student’s t-test was used to calculate the statistical sig-
nificance between the groups. The tumor volume was
analyzed by a two-sided t-test.
Results
Lapatinib induces NF-κB activation independently of
EGFR/HER2 inhibiton
To address whether lapatinib can induce NF-κB activa-
tion in both HER2-positive and HER2-negative breast
cancer cells, its effect on p65 Ser536 phosphorylation, a
critical IKK complex-mediated modification for NF-κB
activity [25], was examined. Lapatinib markedly induced
p65 Ser536 phosphorylation in HER2-positive SkBr3 and
BT474 breast cancer cell lines (Figure 1A) and in HER2-
negative MDA-MB-231 and MDA-MB-468 cell lines
(Figure 1B). To further examine the activation of NF-κB
after long-term treatment with lapatinib acquired resist-
ant clones of SkBr3 and BT474 cell lines, named SkBr3/
Lap and BT474/Lap respectively, were established by
chronic treatment with increasing concerntrations of
lapatinib. p65 Ser536 phosphorylation remained higher
in both SkBr3/Lap and BT474/Lap clones compared
with their parent cells (Figure 1A) and IKK inhibitors
suppressed this phosphorylation in SkBr3/Lap#6 cells
(Figure 1C), supporting that lapatinib resistance induced
activation of the IKK/NF-κB axis. To examine whether
this event occurs in HER2-negative breast cancer cells,lapatinib-selected clones from triple-negative MDA-MB-
231, MDA-MB-468, and HBL100 cell lines, named 231/
Lap, 468/Lap, and HBL100/Lap respectively, were also
established. The induction of p65 phosphorylation by
lapatinib was also observed in these lapatinib-selected
TNBC clones (Figure 1D) and this phosphorylation in
SkBr3/Lap#6, BT474/Lap#3, and 231/Lap#6 cells was
reduced once lapatinib was withdrawn from the culture
medium (Additional file 1: Figure S1), suggesting that
lapatinib activates NF-κB independently of HER2 inhib-
ition. In addition, EGFR specific inhibitors gefitinib
(Gef )- or erlotinib (Erl)-selected clones from BT474 and
MDA-MB-231 cells were established. However, these
two EGFR inhibitors did not increase p65 Ser536 phos-
phorylation. These results suggest that inhibition of
EGFR and HER2 was not involved in the lapatinib-
induced NF-κB activation.
In addition to phosphorylation at Ser536, p65 phos-
phorylations at other residues, such as Ser276 and
Ser529, are also critical for the NF-κB activation in re-
sponse to various stimuli [26,27]. However, p65 Ser276
phosphorylation (Additional file 1: Figure S2A and S2B)
and Ser529 (Additional file 1: Figure S2C and S2D) were
suppressed rather than increased in the SkBr3/Lap,
BT474/Lap and 231/Lap clones. To further confirm
NF-κB activation, the nuclear localization of p65 in
these lapatinib-treated cells was examined. Our data
showed that the nuclear p65 level was significantly
higher in 231/Lap#2 clone than in the MDA-MB-231 cells
(Figure 1G), and this event was observed in immunofluor-
escence staining/confocal microscope analysis (Figure 1H).
All these results indicated that lapatinib possesses off-
target activity to induce p65 phosphorylation and nuclear
translocation in both HER2-positive and TNBC cells.
We next investigated whether the lapatinib-activated
NF-κB can mediate its downstream gene expressions.
cDNA microarray analysis was employed to profile gene
expressions that were upregulated more than two folds
in lapatinib-resistant SkBr3 and BT474 cells (Additional
file 2: Table S1). Then, this data were analyzed with In-
genuity Pathway Analysis (IPA) to identify which genes
are regulated by NF-κB in response to lapatinib treat-
ment. The result showed 24 genes upregulated by NF-κB
(Figure 2A), and some well-documented NF-κB-target
genes were further validated. The mRNA levels of IL-
1β, IL-6 and TRAF1 in SkBr3/Lap#6 cells were higher
than those in SkBr3 cells (Figure 2B-D) and were re-
duced by p65 shRNA (Figure 2F-H). Similarly, IL-1β,
IL-6 and COX-2 transcripts were also induced in 231/
Lap#2 cells (Figure 2B, C, and E) and were inhibited by
p65 shRNA (Figure 2F, G, and I). IL-1β and IL-6 tran-
scripts were also increased by short-term treatment with
lapatinib in SkBr3 and MDA-MB-231 cells (Additional
file 1: Figure S3A and S3B) and were reduced in
Figure 1 Lapatinib induces NF-κB activation in an off-target manner. (A-F) Lapatinib induces p65 phosphorylation in both HER2-positive
and triple-negative breast cancer cells. HER2-postive SkBr3 and BT474 breast cancer cells were treated with or without 1 μM lapatinib for two
days, and SkBr3/Lap and BT474/Lap cells were cultured in the presence of 1 μM lapatinib (A). Triple-negative MDA-MB-231 and MDA-MB-468
breast cancer cells were treated with 1 μM lapatinib for the indicated days (B). SkBr3/Lap#6 cells were treated with 10 μM IKK inhibitor II, 20 μM
IKK inhibitor X, or 5 μM IKK inhibitor VII for two days (C). Lapatinib-selected clones established from triple-negative MDA-MB-231, MDA-MB-468,
and HBL-100 cell lines were cultured in the presence of 1 μM lapatinib (D). Erlotinib- and gefitinib-selected clones established from BT474 (E) and
MDA-MB-231 cells (F) were cultured in the presence of 1 μM respective drugs. Total lysates prepared from these cells were subjected to Western blot
analysis with the indicated antibodies for NF-κB phosphorylation and expression. (G, H) Lapatinib treatment induces p65 nuclear translocation.
MDA-MB-231 and 231/Lap#2 cells were subjected to nuclear/cytoplasmic fractionation followed by Western blot analysis with the indicated antibodies.
Lamin and tubulin function as control markers for nuclear and cytosolic extraction, respectively (G). MDA-MB-231 and 231/Lap#6 cells were fixed
followed by staining with anti-p65 antibody and DAPI (fluorescent dye for nucleus staining) in confocal microscope analysis (H). DAPI, diamidino-2-
phenylindole; IKK, IKB kinase; HER2, human epidermal growth factor receptor 2.
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and 231/Lap#2 cells (Additional file 1: Figure S3C and
S3D). IL-6 promoter activity was dramatically higher in
231/Lap#6 cells than in the parental cells. Mutation of
the NF-κB-binding site almost abolished this effect
(Figure 2J), indicating that lapatinib-activated NF-κB
mediated the gene transcription in response to lapatinib
treatment. The protein levels of COX-2 and TRAF1
were also increased in both 231/Lap#2 and 231/Lap#6
cells and were suppressed by p65 shRNA (Figure 2K).
These results show that lapatinib treatment not only
activates NF-κB but also subsequently induces various
NF-κB-targeted gene expressions.Induction of NF-κB by lapatinib involves rapid IκBα turn-
over and tyrosine phosphorylation
Although activation of the IKK complex and its down-
stream IκBα Ser32/36 phosphorylations were found in
SkBr3/Lap and BT474/Lap clones, reduction of IκBα
was not seen (Figure 3A and B). Similar phenomena
were also observed in lapatinib-treated clones of MDA-
MB-231 and MDA-MB-468 (Figure 3C and D). There-
fore, whether IκBα degradation was involved in
lapatinib-induced NF-κB activation was further investi-
gated. Since IκBα is also a downstream target gene of
NF-κB, we hypothesized that lapatinib still can induce
IκBα degradation but the protein level of IκBα was
Figure 2 Expressions of NF-κB target genes are elevated by lapatinib in both HER2-positive and –negative breast cancer cells. (A) Total RNA
extracted from two pairs of parental and lapatinib-resistant cells (SkBr3 and SkBr3/Lap#6; BT474 and BT474/Lap#3) was subjected to reverse transcription
followed by cDNA microarray analysis. Gene expressions of NF-κB target gene with more than two folds change were analyzed with Ingenuity Pathway
Analysis (IPA). (B-E) Total RNA extracted from SkBr3, MDA-MB-231, and their lapatinib-selected clones was subjected to RT-qPCR analysis for mRNA
levels of IL-1β (B), IL-6 (C), TRAF-1 (D) and COX-2 (E). (F-I) SkBr3/Lap#6 and 231/Lap#2 cells were infected with lentiviral shRNA against luciferase (shLuc)
or p65 (shp65) for three days, and then total RNA was extracted and subjected to RT-qPCR analysis for mRNA levels of IL-1β (F), IL-6 (G), TRAF-1
(H) and COX-2 (I). (J) MDA-MB-231 and 231/Lap#6 cells were transiently transfected with the luciferase reporter gene of IL-6 promoter containing
wild-type (WT) or mutation of NF-κB-binding sites (NF-κBmut). The promoter activity of IL-6 was normalized with β-galactosidase activity. (K) MDA-MB-
231 and 231/Lap cells were infected with lentivirus of shRNA against luciferase (shLuc) or p65 (shp65) for three days, and then whole protein lysates
were prepared and subjected to Western blot analysis with antibodies against indicated molecules. shRNA, short hairpin RNA.
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to de novo synthesis. To prove this hypothesis, we
treated cells with cycloheximide to inhibit protein bio-
synthesis and monitored the IκBα level by Western blotanalysis. In parental SkBr3 (Figure 3E, left) and MDA-
MB-231 (Figure 3F, left) cells, IκBα remained unchanged
after treatment with cycloheximide; however, in SkBr3/
Lap (Figure 3E, right) and 231/Lap (Figure 3F, right)
Figure 3 Activation of NF-κB by lapatinib involves rapid IκBα turnover. (A-D) Whole cell lysates from parental and lapatinib-selected cells of
HER2-positive SkBr3 (A) and BT474 (B) cell lines and triple–negative MDA-MB-231 (C) and MDA-MB-468 (D) cell lines breast cancer cells were
harvested and subjected to Western blot analysis with specific antibodies for phosphorylation and protein expression of IKKα/β, IκBα, and tubulin.
(E,F) SkBr3 (E), MDA-MB-231 (F), and their lapatinib-treated clones were treated with 25 μM cycloheximide for 0, 0.5 and 1 hours. The protein
expression of IκBα was examined by Western blot analysis and quantified. (G,H) SkBr3/Lap (G), MDA-MB-231, and 231/Lap#2 (H) cells were treated
with 1 μM MG-132 for 0, 0.5 and 1 hours. The protein expression and phosphorylation of IκBα were examined by Western blot analysis. (I,J) Total
RNA was extracted from parental and lapatinib-resistant clones of SkBr3 and MDA-MB-231 cells (I) and from SkBr3/Lap#6 and 231/Lap#2 cells
infected with lentivirus of Luc or p65 shRNA for three days (J). The expression of IκBα mRNA was analyzed by RT-qPCR. (K) MDA-MB-231 and
231/Lap cells were infected with lentivirus of Luc or p65 shRNA for three days. The protein expression of IκBα was analyzed by Western blot
analysis. shRNA, short hairpin RNA.
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mide. Furthermore, the IκBα level and Ser32/36 phos-
phorylations in SkBr3/Lap#6 (Figure 3G) and in 231/
Lap#2 (Figure 3H) cells were also elevated when cells were
treated with proteasome inhibitor MG132. These results
suggest that IκBα protein was continuously degraded but
was also re-synthesized simultaneously back to the steady
state in response to lapatinib treatment. In support to this
notion, an increase in IκBα mRNA level was found in bothSkBr3/Lap and 231/Lap clones (Figure 3I), and silencing
of p65 expression can down-regulate the transcripts
(Figure 3J) and protein expression (Figure 3K) of IκBα.
These results suggest that lapatinib-induced NF-κB ac-
tivation still involved IκBα protein degradation, and the
unchanged IκBα level may be due to the elevation of
de novo gene expression.
In addition to the IκBα phosphorylations at Ser32/36
by the IKK complex, phosphorylation at Tyr42 by Src
Chen et al. Breast Cancer Research 2013, 15:R108 Page 8 of 14
http://breast-cancer-research.com/content/15/6/R108can also lead to NF-κB activation by reducing the pro-
tein interaction between p65 and IκBα [28,29]. c-Src/Lck
is activated in response to stresses, such as hypoxia and
X-rays, and causes Tyr42 phosphorylation of IκBα with-
out its protein degradation [28,29]. To clarify whether
SFK also participates in the NF-κB activation in lapatinib-
resistant cells, the SFK activity in resistant cells was exam-
ined. Our data revealed that tyrosine phosphorylation of
SFK is increased in lapatinib-treated clones of SkBr3,
BT474, and MDA-MB-231 (231) cells (Figure 4A). The
phosphorylation of SFK was increased by lapatinib
treatment for a few days in the parental BT474 cells
(Additional file 1: Figure S4A), but was reduced in
lapatinib-resistant clones of SkBr3 and MDA-MB-231
cells upon removal of lapatinib from the culture medium
(Additional file 1: Figure S4B). Short-term treatment with
lapatinib can also induce IκBα Tyr42 phosphorylation in
both HER2-positive SkBr3 and HER2-negative MDA-MB-
231 cells (Figure 4B and Additional file 1: Figure S4C),
which was also observed in SkBr3/Lap#6 and 231/Lap
clones (Figure 4C). Both p65 Ser536 phosphorylation and
IκBα Tyr42 phosphorylation in lapatinib-treated SkBr3,
BT474 and MDA-MB-231 cells were suppressed by Src
inhibitors, including dasatinib (Dasa), AZD0530 (AZD)
and PP2 (Figure 4D), suggesting that the lapatinib-
induced NF-κB activation is Src-dependent. Anti-IκBα
immunoprecipitates were immunoblotted with anti-p65
antibody to further confirm the involvement of Tyr42Figure 4 SFK activation contributes to induction of NF-κB by lapatinib
lapatinib-selected clones were collected followed by Western blot analysis
MDA-MB-231 cells were treated with lapatinib for the indicated time point
protein expression were detected by Western blot analysis. (C) Whole cell l
were harvested and subjected to Western blot analysis with specific antibo
BT474, MDA-MB-231 and their lapatinib-selected clones were treated with
were prepared and subjected to Western blot analysis with anti-phospho-p
protein from total lysates of MDA-MB-231 and 231/Lap cells was immunop
for IκBα/p65 protein interaction. SFK, Src family kinase.phosphorylation of IκBα in NF-κB activation, and the
interaction between IκBα and p65 was reduced in 231/
Lap cells compared to parental cells (Figure 4E). These
results suggest that Src-dependent Tyr42 phosphoryl-
ation of IκBα may render the de novo IκBα unable to
feedback repress NF-κB activity.
Activated NF-κB becomes the Achilles’ heel in lapatinib-
treated HER2-negative breast cancer cells
Since NF-κB is activated in both HER2-positive and
HER2-negative breast cancer cells in response to lapati-
nib treatment, we next examined the effect of p65
shRNA on the cell viability of SkBr3 and MDA-MB-231
cells and their lapatinib-resistant clones in both the
presence and absence of lapatinib. Although silencing of
p65 reduced cell viability in SkBr3 but not in MDA-MB-
231 cells, treatment with lapatinib enhanced their sensitiv-
ity to p65 shRNA in both cell lines (Figure 5A and B).
The cell viability inhibition by p65 shRNA was more dra-
matic in both SkBr3/Lap#6 and 231/Lap#2 cells in the
presence of lapatinib, but the suppression was attenuated
after lapatinib withdrawal (Figure 5A and B). Similarly,
lapatinib also enhanced the sensitivity of MDA-MB-231
cells to IKKα inhibitor (Figure 5C). The 231/Lap#2 cells
also showed greater sensitivity to IKK inhibitor than their
parental cells, and this effect was diminished upon lapati-
nib withdrawal from the culture medium (Figure 5C).
These results suggest a critical role of IKK/NF-κB. (A) Whole cell lysates of SkBr3, BT474, MDA-MB-231 and their
with anti-phospho-SFK and anti-tubulin antibodies. (B) SkBr3 and
s. Phosphorylation of p-SFK and p-IκBα as well as IκBα and tubulin
ysates from SkBr3, MDA-MB-231 cells and their lapatinib-treated clones
dies for phosphorylation and/or expression of SFK and IκBα. (D) SkBr3,
the SFK inhibitors, dasatinib (Dasa) or AZD0530 (AZD). Total lysates
65 (Ser536), anti-phospho-SFK and anti-tubulin antibodies. (E) IκBα
recipitated followed by Western blot analysis with anti-p65 antibody
Figure 5 NF-κB functions as a critical regulator for cell survival in response to lapatinib treatment. (A,B) SkBr3 (A), MDA-MB-231 (B), and their
lapatinib-treated derivatives were infected with lentivirus of Luc or p65 shRNA in the presence or absence of 1 μM lapatinib for three days. Cell viability
and p65 protein expression were determined by MTT and Western blot analyses, respectively. (C) MDA-MB-231 and 231/Lap cells were treated with
10 μM IKKα inhibitor in the presence or absence of 1 μM lapatinib for 24 hours. The cell viability was determined by MTT assay. (D-I) Parental and
lapatinib-selected cells of SkBr3 (D-F) and MDA-MB-231 (G-I) cells were treated with various doses of proteasome inhibitors, including MG-132
(D and G), lactacystin (E and H) and proteasome inhibitor I (F and I) in the presence or absence of lapatinib for 24 hours and then subjected to MTT
assay. (J) MDA-MB-231 cells and their lapatinib-treated clones were treated with or without the indicated concentrations of bortezomib for 48 hours. Two
apoptotic markers, PARP and caspase 3 cleavages, were then examined by Western blot analysis with anti-PARP and anti-caspase 3 specific antibodies.
*, P <0.05; **, P <0.01; ***, P <0.001. IKK, IKB kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PARP, poly ADP ribose polymerase.
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http://breast-cancer-research.com/content/15/6/R108activation in the lapatinib-resistance of both HER2-
positive and TNBC cells. Prevention of IκBα degradation
via inhibiting proteasome activity efficiently impairs NF-
κB activation. Treatment with proteasome inhibitors in-
cluding MG-132, Lactacystin and Proteasome inhibitor I
(PSI) did not further enhance the anti-cancer activity of
lapatinib in SkBr3 cells due to the high sensitivity of this
cell line to lapatinib (Figure 5D-F). Nevertheless, these
proteasome inhibitors circumvented the lapatinib resist-
ance in SkBr3/Lap#6 cells but this effect was not observed
after lapatinib was removed from the culture medium
(Figure 5D-F). These results suggest that inhibition of
NF-κB activation by proteasome inhibitors may overcome
the acquired lapatinib resistance in HER2-positive breast
cancer cells. Our data further showed that the cell viability
of MDA-MB-231 cells was little affected by proteasome
inhibitors, but the inhibition was significantly enhanced
by lapatinib (Figure 5G-I). Interestingly, proteasome in-
hibitors dramatically inhibited the cell viability of 231/
Lap#2 cells in the presence of lapatinib, and lapatinib
withdrawal diminished the sensitivity (Figure 5G-I).
Poly ADP ribose polymerase (PARP) and caspase-3 pro-
tein cleavages induced by the proteasome inhibitor bor-
tezomib were also obviously enhanced in 231/Lap clones
(Figure 5J). These results not only suggest that lapatinib
can enhance the oncogenic addiction of TNBC cells to
NF-κB, but also imply that co-treatment of lapatinib may
enhance their sensitivity to proteasome inhibitors.
Lapatinib treatment sensitizes TNBCs to proteasome
inhibitors
Next, we tested our hypothesis that lapatinib can enhance
or switch the oncogenic addiction of TNBC cells to NF-
κB and, in turn, enhance their sensitivity to proteasome
inhibitors both in vitro and in vivo. Bcl-2 is a direct tran-
scription target of NF-κB and responsible for anti-
apoptosis [30]. Our data showed that the anti-apoptotic
Bcl-2 expression was induced by treatment with 1 μM
lapatinib for three days in MDA-MB-231 cells and this
effect was blocked by bortezomib (Figure 6A). Never-
theless, lapatinib and bortezomib in combination, but
not individually, can induce pro-apoptotic Bax expres-
sion (Figure 6A) and enhance bortezomib-induced PARP
and caspase-3 cleavages in MDA-MB-231 and HS-578
T cell lines, further demonstrating the synergistic effect of
lapatinib on the proteasome inhibitor-induced apoptosis.
In clonogenic assays, lapatinib and gefitinib did not reduce
the viability of MDA-MB-231 and HS-578 T TNBC cell
lines due to HER2-negative expression and the dispensable
role of EGFR in these cells (Figure 6B). However, pretreat-
ment with lapatinib but not gefitinib can enhance the anti-
cancer activity of MG-132 and bortezomib (Figure 6B).
To further confirm this synergistic activity in vivo,
MDA-MB-231 cells were injected into the mammary fatpad of SCID mice followed by treatment with lapatinib,
bortezomib or lapatinib plus bortezomib, respectively.
Treatment with bortezomib and lapatinib combined, but
not individually, significantly suppressed the tumor growth
(Figure 6C). The nuclear localization of p65 was enhanced
in the lapatinib-treated tumors, and this effect was inhib-
ited by treatment with bortezomib (Figure 6D). The com-
bined treatment not only inhibited NF-κB but also induced
Bax expression in the xenograft tumor tissues (Figure 6D).
These results suggest that lapatinib may sensitize TNBC
cells to proteasome inhibitors by increasing their oncogene
addiction to NF-κB.
Discussion
Unlike the luminal or HER2-enriched subtypes, charac-
terized by the expression of hormone receptors or
HER2, respectively, TNBC cells are almost insensitive to
the established endocrine treatments and HER2-targeted
agents due to the lack of known oncogenic drivers. Al-
though synthetic lethal targeting of BRCA-deficient cells
with PARP inhibitors has been proposed as a promising
therapeutic strategy for TNBC in preclinical studies [31],
the low mutation rate (near 20%) of BRCA1/2 [32] sug-
gests that PARP inhibitors may only benefit a small
number of such patients. New therapeutic strategies are
therefore urgently needed for such patients.
Recent results from gene expression profiling analysis
revealed that the NF-κB pathway may represent a key
regulator of TNBC [33]. Various small molecules inhibit-
ing NF-κB, including aspirin [34], genistein [35] and syn-
thesized phospho-ibuprofen [36], have shown significant
anti-tumor activity in preclinical studies for treating
TNBC tumors. These studies revealed NF-κB as a poten-
tial therapeutic target for TNBC patients. Bortezomib
(Velcade), a potent inhibitor of the 26S proteasome, has
been approved for melanoma and hematopoietic malig-
nancies. Preclinical studies have further demonstrated
that bortezomib also showed remarkable anti-tumor ac-
tivity against TNBC in vitro [37]. However, bortezomib
alone [16] or in combination with aromatase inhibitor or
tamoxifen [38] failed to show a significant clinical bene-
fit in patients with metastatic breast cancer. The mo-
lecular heterogeneity and complexity of addicted status
in TNBCs might explain these disappointing results [39].
Therefore, strategies to trap cancer cells to the NF-κB
signal pathway by an artificial addiction shift may be
able to potentiate the anti-tumor activity of proteasome
inhibitors [40]. In this study, we reported that the off-
target activity of lapatinib in augmenting NF-κB activity
may enhance the therapeutic benefits of bortezomib for
TNBC patients.
Induction of NF-κB activity was observed in lapatinib-
treated HER2-positive breast cancer cells,and, thus, has
been considered as a potential target for circumventing
Figure 6 Lapatinib significantly enhances the anti-tumor activity of proteasome inhibitors in vitro and in vivo. (A) Triple-negative MDA-
MB-231 and HS-578 T breast cancer cells were pre-treated with 1 μM lapatinib for three days followed by addition or not of 50 nM bortezomib
for 48 hours. Protein cleavage of PARP and caspase 3 were then examined by Western blot analysis with anti-PARP and anti-caspase 3 specific
antibodies. (B) Triple-negative MDA-MB-231 and HS-578 T breast cancer cells were pre-treated with 1 μM lapatinib or 1 μM gefitinib for three days
followed by addition or not of 0.3 μM MG-132 or 50 nM bortezomib for seven days. The cell viability was determined by crystal violet staining.
(C,D) MDA-MB-231 cells were injected into the mammary fat pad of SCID mice followed by treatment with lapatinib, bortezomib or lapatinib plus
bortezomib, respectively. The growth rate of xenograft tumor was determined by measurement of tumor size (C). The expression of p65 and
apoptotic protein Bax in the xenograft tumor in response to these treatments was examined by immunohistochemical staining with anti-p65 and
anti-Bax specific antibodies (D). PARP, poly ADP ribose polymerase; SCID, severe combined immunodeficiency.
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the involvement of NF-κB activation in contributing to
lapatinib resistance in HER2-positive breast cancer cells(Figure 5A), our data also showed that treatment with
lapatinib elevates NF-κB activity in TNBC cell lines
(Figure 1), uncovering the off-target effect of lapatinib
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http://breast-cancer-research.com/content/15/6/R108on NF-κB activation. Lapatinib was tested as monother-
apy or in combination with other systemic therapies in
phase II trials for TNBC or HER2-negative breast cancers
[41,42]. Inhibition of EGFR by lapatinib was considered as
a promising therapeutic strategy for TNBC patients [43]
since EGFR is overexpressed in 80% of TNBC [44]. Unfor-
tunately, results from most of these studies showed lim-
ited clinical benefits for these patients. Nevertheless, the
increased NF-κB activity renders lapatinib-treated TNBCs
more vulnerable to NF-κB inhibition by p65 shRNA or
proteasome inhibitors (Figure 5). These results strongly
suggest that lapatinib may augment the oncogenic addic-
tion of cancer cells to NF-κB, which may become the
Achilles’ heel in TNBCs. The switch of survival pathway
to NF-κB was also observed in various types of solid tu-
mors during the acquisition of resistance to camptothe-
cin and rendered these camptothecin-resistant cells
more sensitive to the NF-κB inhibitor dehydroxymethy-
lepoxyquinomicin (DHMEQ) [45]. Our results further
demonstrated that co-treatment with lapatinib can sensitize
TNBC cells to proteasome inhibitors both in vitro and
in vivo (Figure 6), suggesting that the artificial trap of can-
cer cells to NF-κB signaling by lapatinib may be a potential
strategy to increase the anti-tumor activity of bortezomib
for TNBC patients.
Several lines of evidence from this study and the litera-
ture indicate that the induction of NF-κB by lapatinib is
independent of EGFR and HER2 inhibition. First, re-
gardless of the HER2 status, lapatinib-induced NF-κB
activation was found in both HER2-positive and TNBC
cells in this study (Figure 1A and B, respectively).
Second, although lapatinib also possesses inhibitory
activity against EGFR, our data showed that treatments
with specific EGFR inhibitors, including erlotinib and
gefitinib, suppress rather than induce p65 phosphoryla-
tions in both HER2-positive BT474 and triple-negative
MDA-MB-231 breast cancer cells (Figure 1E and F).
Also, only lapatinib but not gefitinib can synergize the
anti-tumor activity of MG-132 in TNBC cells (Figure 6B).
Third, inhibition of either HER2 [46] or EGFR [47] by
its specific siRNA has been reported to decrease but not
increase NF-κB activity. Similar to this EGFR/HER2-
independent role in NF-κB activation, lapatinib has also
been reported to up-regulate the expression of pro-
apoptotic TRAIL death receptors DR4 and DR5 through
an off-target mechanism in colon cancer cells and, thus,
sensitizes these cancer cells to TRAIL-induced apoptosis
[21]. The induction of DR5 by lapatinib was evident only
with high drug concentrations (>5 μM) [21]. However,
our data showed that 1 μM of lapatinib is sufficient for
NF-κB activation. Therefore, lapatinib-enhanced NF-κB
activity is unlikely through induction of DR5 expression
although TRAIL has been known to initiate signaling to
NF-κB activation [45].The lapatinib-augmented NF-κB activity, derived from
the EGFR/HER2-independent off target effect, involves
both classic and SFK-mediated NF-κB activation path-
ways. Although our data revealed that reduction of the
IκBα protein level was not accompanied with lapatinib-
induced NF-κB activation, IκBα Ser32/36 phosphoryla-
tions and a higher turnover rate of IκBα were still found
in lapatinib-treated cells, indicating that IκBα degrad-
ation remains necessary for liberating NF-κB. However,
the de novo synthesis of IκBα, which is mediated by
lapatinib-activated NF-κB, accounts for the unchanged
IκBα protein level but did not feedback bind to and in-
hibit NF-κB. Up-regulation of SFK activity has been
found in the acquired lapatinib-resistant cells with HER2
overexpression [48]. Our data further showed that lapa-
tinib also activates SFK in both HER2-positive and
TNBC cells to mediate IκBα Tyr42 phosphorylation,
which prevents the feedback inhibition of NF-κB from
IκBα protein binding [28,29]. These events lead to the
constitutive activation of NF-κB in lapatinib-treated
cells. Interestingly, bortezomib not only inhibits p65
phosphorylation but also reduces SFK tyrosine phos-
phorylation (data not shown). It suggests that the anti-
tumor activity of bortezomib with co-treatment of lapati-
nib in our study may be partly attributed to inhibition of
SFK activity by bortezomib. However, the potential possi-
bility and molecular mechanisms underlying bortezomib-
mediated SFK inhibition await further investigations.
Conclusions
In conclusion, the off-target activity of lapatinib switches
or enhances the oncogenic addiction of TNBC cells to NF-
κB in a SFK-dependent manner. Therefore, co-treatment
with lapatinib may synergize the anti-cancer activity of pro-
teasome inhibitors, which may provide a novel and feasible
way for treating TNBCs.
Additional files
Additional file 1: Figure S1. Lapatinib withdrawal reduced the Ser536
phosphorylation of p65 in lapatinib-selected clones. SkBr3/Lap#6, BT474/
Lap#3, and 231/Lap#6 cells were cultured in the absence of lapatinib for
one or three days, and total lysates were prepared and subjected to
Western blot analysis with the indicated antibodies. Figure S2. Lapatinib
does not induce the Ser276 and Ser529 phosphorylations of p65 in breast
cancer cells. Whole cell lysates in SkBr3, BT474, MDA-MB-231 and their
lapatinib-treated derivatives were harvested. Total lysates from SkBr3 (A)
and MDA-MB-231 (B) cells treated with 10 ng/ml TNF-α for 10 minutes
are used as a positive control. Phosphorylation of p65 at Ser276 (A-B) and
Ser529 (C-D) was examined by Western blot analysis. Figure S3. The
effect of lapatinib on the expression of IL-1β and IL-6 transcripts in SkBr3,
MDA-MB-231 cells, and their lapatinib-treated clones. A-B, SkBr3 and
MDA-MB-231 cells were treated with lapatinib for 24 hours. C-D, SkBr3/
Lap#6 and 231/Lap#2 cells were cultured in the presence or absence of
lapatinib for 24 hours. Total RNA was extracted and subjected to RT-qPCR
analysis for mRNA levels of IL-1β (A and C) and IL-6 (B and D). Figure S4.
The effect of lapatinib on the activation of SFK and IκBα Tyr42 phosphor-
ylation in SkBr3, MDA-MB-231 cells, and their lapatinib-treated clones.
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lapatinib for the indicated number of days. B, SkBr3/Lap#6 and 231/
Lap#12 cells were cultured in the presence or absence of lapatinib for
the indicated number of days. Total protein lysates were extracted and
subjected to Western blot analysis with the indicated antibodies.
Additional file 2: Table S1. Microarray analysis of upregulated gene
expression profile in lapatinib-resistant SkBr3 and BT474 breast cancer
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